ArticleBMC gastroenterology2025
The prevalence and associated factors of autoimmune gastritis: single-center, hospital-based prospective study in China.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAutoimmune gastritis (AIG) is a chronic immune-mediated disease characterized by anti-parietal cell antibody (PCA) and corpus-predominant atrophy. However, epidemiological data on AIG remain limited in China where the prevalence of Helicobacter pylori (H. pylori) is high. This study aimed to estimate the prevalence and associated factors of AIG in a hospital-based population.
methodsThis study enrolled subjects who underwent the first upper gastrointestinal endoscopy at Renji Hospital from August 2023 to August 2025. All participants received serological tests and histopathological evaluation, and demographic information and medical history were recorded. Individuals with prior history of H. pylori eradication were excluded. AIG was diagnosed by PCA positivity with corpus-dominant atrophy and/or intestinal metaplasia, regardless of H. pylori status.
resultsA total of 1378 subjects (mean age 53.7 years, 56.7% female) were included. The positive rates of PCA and IFA were 12.6% and 1.4%, respectively. Compared with PCA-negative individuals, PCA-positive subjects had significantly lower H. pylori infection rates and higher frequencies of coexisting autoimmune diseases, particularly autoimmune thyroid diseases (AITD). Overall, 54 subjects (3.9%) met the diagnostic criteria for AIG (mean age 56.3 years, 70.4% female), with 29.6% anemia, 27.8% coexisting AITD. Among AIG patients, intestinal metaplasia was present in 81.5%, pseudo-pyloric metaplasia in 42.6%, gastric neuroendocrine cell hyperplasia in 27.8%, and fundic gland polyps in 11.1%.
conclusionThis study provides a comprehensive estimate of AIG prevalence in Chinese population, identifying key associated factors, offering valuable data for early screening and risk assessment of AIG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.